tbuckley/cabot-search huggingface dataset:
Randomized Multicenter Phase II Trial of Oxaliplatin Plus Irinotecan Versus Raltitrexed as First-Line Treatment in Advanced Colorectal Cancer
Authors: Werner Scheithauer, Gabriela V. Kornek, Markus Raderer, Herbert Ulrich-Pur, Wolfgang Fiebiger, Claudia Gedlicka, Birgit Schüll, Stefan Brugger, Bruno Schneeweiss, Fritz Lang, Alfred Lenauer, Dieter Depisch
Journal: Journal of Clinical Oncology (2002)

PURPOSE: Irinotecan and oxaliplatin are two new agents with promising activity in advanced colorectal cancer. Based on preclinical and clinical evidence that both drugs act synergistically, a randomized phase II study was initiated to investigate the therapeutic potential and tolerance of this combination in the front-line setting. PATIENTS AND METHODS: Ninety-two patients with previously untreated, measurable disease were randomized to receive biweekly oxaliplatin 85 mg/m 2 plus irinotecan 175 mg/m 2 or raltitrexed 3 mg/m 2 given on day 1 every 3 weeks. Upon development of progressive disease, second-line treatment with the opposite arm was effected. RESULTS: Patients allocated to oxaliplatin/irinotecan had a significantly better radiologically confirmed response rate (43.5% v 19.6%; P = .0025) and longer progression-free survival (median, 7.1 v 5.0 months; P = .0033). Improvement in overall survival, however, did not reach the level of significance (median, 16.0 v 16.5 months; P = .3943). The response rate after cross-over was 33.3% (eight of 24) for assessable patients treated with oxaliplatin/irinotecan compared with 14.2% (three of 21) for those treated with second-line raltitrexed. Oxaliplatin/irinotecan caused more hematologic and gastrointestinal toxicities, necessitating dose reductions in 10 of the first 20 patients. After adjustment of the irinotecan starting dose from 175 to 150 mg/m 2 , tolerance of treatment was acceptable; the most commonly encountered events (all grades) were neutropenia (81%), alopecia (65%), nausea/emesis (62%), peripheral sensory neuropathy (62%), and diarrhea (46%). CONCLUSION: Oxaliplatin/irinotecan seems beneficial as first-line therapy in advanced colorectal cancer, with an acceptable toxicity profile at the reduced irinotecan dose level. Its promising therapeutic potential is supported by the high response activity noted in the raltitrexed control arm after cross-over, which may also explain the lack of a difference in overall survival.
Abstract 4237: CC chemokines are differentially expressed in breast cancer and are associated with racial disparity
Authors: Jeronay K. Thomas, Hina Mir, Neeraj Kapur, Shailesh Singh
Journal: Cancer Research (2019)

Abstract Despite recent advances in diagnosis and treatment Breast cancer (BrCa) still impacts women’s lives and this impact is disproportional in African Americans (AA) compared to European Americans (EA). Addressing socioeconomic and behavioral status has not reduced the race-specific gap in BrCa outcome, suggesting contribution of biological differences in BrCa disparity. We have previously shown involvement of chemokines in the pathogenesis of BrCa. In this study, we have determined the expression of CC chemokines in BrCa tissues and normal tissues utilizing the ONCOMINE database. Further, we determined clinical parameters associated with the CC chemokines overexpressed in BrCa tissues using The Cancer Genome Atlas (TCGA). Additionally, using Bc-GenExMiner and KMplotter we determined the effects of CC chemokines on reoccurrence, overall and relapse-free survival. Our analysis shows overexpression of CCL5, CCL7, CCL11, CCL17, CCL20, CCL22 and CCL25 mRNA in BrCa tissues compared to normal. Overexpression of CCL21 and CCL22 were significantly correlated with metastatic recurrence. High mRNA levels of CCL7, CCL8, CCL17, CCL20 and CCL25 predicted a decrease in overall survival and CCL7 and CCL8 expression showed a trend in decreased relapse-free survival. Furthermore, overexpression of CCL17 and CCL25 was associated with decreased overall survival in AA whereas in EA, CCL8 was associated with a decrease in overall survival. Interestingly, expression of CCL5, CCL8, CCL17, CCL20 and CCL25 were highest in TNBC tissues. Expression of CCL11 and CCL22 were associated with HER2. In addition to these, there was an association with CC chemokines expression with age in BrCa. Higher CCL11 expression was noted in younger women and CCL8, CCL20, CCL22 and CCL25 expression was higher in older women. Furthermore, CCL25 was significantly elevated and CCL8 was nearly significant in AA tissues when compared to EA. Expression of CCL7, CCL8, and CCL25 were associated with stage. In conclusion, our analysis suggests an association of CC chemokines in BrCa progression, overall survival and observed disparity in disease outcome between AA and EA patients. Citation Format: Jeronay K. Thomas, Hina Mir, Neeraj Kapur, Shailesh Singh. CC chemokines are differentially expressed in breast cancer and are associated with racial disparity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4237.
Improving growth status of Asian refugee children in the United States
Authors: R. Yip
Journal: JAMA (1992)

<h3>Objective.</h3> —To analyze the trend and pattern of the nutrition status of Southeast Asian refugee children and other low-income children in the United States. <h3>Design.</h3> —Descriptive analysis of the growth data from the Pediatric Nutrition Surveillance System of the Centers for Disease Control, Atlanta, Ga, from 1980 through 1989. <h3>Subjects.</h3> —Children under 5 years of age from low-income families enrolled in public health clinics in 12 selected states. <h3>Measurements and Main Results.</h3> —Asian refugee children experienced a progressive and significant decline in the prevalence of low birth weight, low height-for-age, and low weight-for-age, while these nutritional indexes remained stable for low-income white, black, and Hispanic children. By 1989, the growth status of Asian children was near that of other ethnic groups. <h3>Conclusions.</h3> —The marked improvement of growth status among Asian refugee children over a short period suggests that the poor growth status often observed among recently immigrated Asian children is primarily related to nutritional and health factors, rather than genetic factors. In assessing the growth of Asian or immigrant children, it would be helpful to take their family and early childhood background into account. (<i>JAMA</i>. 1992;267:937-940)
PRESIDENT'S REPORT
Authors: CYRUS C. STURGIS
Journal: Annals of Internal Medicine (1955)

College News Notes1 August 1955PRESIDENT'S REPORTCYRUS C. STURGIS, M.D., F.A.C.P.CYRUS C. STURGIS, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-43-2-xxi SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONIn keeping with the change initiated by my immediate predecessor, Dr. LeRoy H. Sloan, I desire to present a short report at this business session rather than during the Convocation.There are many things that could be discussed at this time. I wish, however, to limit my remarks to a few of our activities which are either new or possess sufficient inherent interest to warrant reiteration. These topics may be enumerated as follows:1. Research Fellowships and Scholarships of the College2. The Residents' Revolving Loan Fund3. The future of the associate membership4. Financial status of the... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1955Volume 43, Issue 2Page: xxi-lxKeywordsFellowshipsForecasting Issue Published: 1 August 1955 PDF downloadLoading ...
186P Bevacizumab in combination with 5-fluorouracil (5-FU) based doublet chemotherapy as neoadjuvant therapy for Chinese patients with previously untreated, unresectable liver-only metastatic colorectal cancer: A multi-center, single-arm phase II study
Authors: D-S. Wan, S-Z. Zhang, Y-Z. Chen, J. Xu, K-X. Tao, G-Y. Wang, C-Y. Hao
Journal: Annals of Oncology (2016)
Hospital Accidents to Children
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Inspiratory Obstruction
Authors: T. J. H. Clark
Journal: BMJ (1970)

Obstructing lesions of the trachea and larynx which cause a predominantly inspiratory obstruction can be satisfactorily diagnosed by measuring both F.I.V.(1) and F.E.V.(1). Chronic airways obstruction involving intrathoracic airways produces a much lower F.E.V.(1)/F.I.V.(1) percentage than normal, whereas obstruction to larynx and trachea causes a raised F.E.V.(1)/F.I.V.(1) percentage. If flow-volume measurements are not available the F.E.V.(1)/F.I.V.(1) percentage should provide a simple and useful method for diagnosis of upper airways obstruction.In one of the patients reported a predominantly inspiratory obstruction caused CO(2) retention. In patients with airways obstruction the correlation between Pco(2) and F.I.V.(1) was found to be the same as between Pco(2) and F.E.V.(1). This suggests that respiratory failure can be caused by either inspiratory or expiratory airways obstruction and that neither is of greater importance in producing CO(2) retention.
The Two-Week-Wait Cancer Initiative in Urology: Useful Modernization?
Authors: Darrell Allen, Rick Popert, Tim O'Brien
Journal: Journal of the Royal Society of Medicine (2004)

The two-week-wait cancer initiative in the UK was designed to speed referral of patients suspected of having cancer and, by so doing, improve their outcome. We reviewed the case notes of all patients referred under this scheme to a single urology department over twelve months. In the department, nearly one-third of new outpatient appointments came under this scheme. 124 patients were referred and all but 7 were seen within the 14-day deadline. In 62 the reason for referral was haematuria, which was macroscopic in 42. Of those with macroscopic haematuria 6 proved to have cancer, newly diagnosed in 4 (2 bladder, 2 renal); no patient with microscopic haematuria had cancer. Of 35 referred with a raised prostate-specific antigen 11 had prostate cancer, in most cases beyond cure. Cancer was found in 1 of 19 patients referred with a testicular mass. In patients referred under the two-week-wait scheme with macroscopic haematuria, cancer is common. Microscopic haematuria is seldom significant. Carcinoma of the prostate is usually advanced and beyond cure at presentation. Among patients referred with scrotal lumps, cancer of the testis is not common. The scheme as a whole is unlikely to improve cancer outcomes. Patients with macroscopic haematuria might be better served by one-stop clinics. For those with testicular lumps, most of which will be benign, the best answer might be direct general practitioner access to scrotal ultrasonography.
Measles Vaccination of Adults in Iceland
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Corrections to “Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results”
Authors: T. Aparicio, O. Bouché, J. Taieb, E. Maillard, S. Kirscher, P -L Etienne, R. Faroux, F. Khemissa Akouz, F. El Hajbi, C. Locher, Y. Rinaldi, T. Lecomte, S. Lavau-Denes, M. Baconnier, A. Oden-Gangloff, D. Genet, E. Paillaud, F. Retornaz, E. François, L. Bedenne
Journal: Annals of Oncology (2018)
Radiology
Authors: B. M. Ellingson, W. B. Pope, A. Lai, P. L. Nghiemphu, T. F. Cloughesy, C. Juhasz, S. Mittal, O. Muzik, D. C. Chugani, P. K. Chakraborty, G. Bahl, G. R. Barger, J. A. Carrillo, A. Lai, P. Nghiemphu, A. Tran, P. Moftakhar, T. F. Cloughesy, W. B. Pope, C. Bruggers, K. Moore, S. Khatua, M. K. Gumerlock, E. Stolzenberg, K.-M. Fung, M. L. Smith, K. Kedzierska, G. Chacko, R. B. Epstein, J. Holter, R. Parvataneni, A. Kadambi, I. Park, A. Elkhaled, E. Essock-Burns, I. Khayal, N. Butowski, K. Lamborn, S. Chang, S. Nelson, E. Sanverdi, B. Ozgen, K. K. Oguz, F. Soylemezoglu, M. Mut, J.-J. Zhu, R. Pfannl, D. Do-Dai, K. Yao, J. Mignano, J. K. Wu, N. Linendoll, K. Beal, T. Chan, Y. Yamamda, A. Holodny, P. H. Gutin, Z. Zhang, R. J. Young, J. M. Lupo, E. Essock-Burns, S. Cha, S. M. Chang, N. Butowski, S. J. Nelson, N. Laperriere, J. Perry, D. Macdonald, W. Mason, J. Easaw, R. Del Maestro, W. Kucharczyk, D. Hussey, K. Greaves, S. Moore, J.-F. Pouliot, P. K. Rauschkolb, S. D. Smith, C. J. Belden, E. C. Lallana, C. E. Fadul, L. Bosscher, M. Slot, E. Sanchez, B. M. Uitdehaag, W. P. Vandertop, S. M. Peerdeman, D. T. Blumenthal, F. Bokstein, M. Artzi, M. Palmon, O. Aizenstein, R. Sitt, K. Gurevich, A. Kanner, Z. Ram, B. Corn, D. Ben Bashat, M. Slot, L. Bosscher, E. Sanchez, B. M. Uitdehaag, W. P. Vandertop, S. M. Peerdeman, N. Martinez, R. Gorniak, L. Tartaglino, M. Scanlan, J. Glass, A. Kleijn, J. W. Chen, P. Z. Sun, J. Buhrman, S. D. Rabkin, R. Weissleder, R. L. Martuza, M. L. Lamfers, G. Fulci, E. C. Lallana, K. A. Brong, K. Hekmatyar, N. Jerome, M. Wilson, C. E. Fadul, R. A. Kauppinen, K. Mok, M. M. Valenca, E. Sherafat, A. Olivier, E. Pentsova, M. Rosenblum, A. Holodny, L. Palomba, A. Omuro, G. J. Murad, A. T. Yachnis, E. M. Dunbar, E. Essock-Burns, Y. Li, J. Lupo, M.-Y. Polley, N. Butowski, S. Cha, S. Chang, S. Nelson, N. Kohler, R. Quisling, E. M. Dunbar, K. R. Swanson, S. Gu, G. Chakraborty, A. Alessio, J. Claridge, R. C. Rockne, M. Muzi, K. A. Krohn, A. M. Spence, E. C. Alvord, A. R. Anderson, P. Kinahan, A. E. Boone, R. C. Rockne, M. M. Mrugala, K. R. Swanson, M. Gutova, V. Khankaldyyan, K. A. Herrmann, I. Harutyunyan, Y. Abramyants, A. J. Annala, J. Najbauer, R. A. Moats, G. M. Shackleford, M. E. Barish, K. S. Aboody
Journal: Neuro-Oncology (2010)
IDENTIFICATION BY PALM AND SOLE PRINTS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Histoplasmosis—Kentucky, 1995
Journal: JAMA (1995)

Histoplasmosis is an infection resulting from inhalation of spores from the dimorphic fungus Histoplasma capsulatum; the condition primarily affects the lungs. During August 1995, the Department for Health Services, Kentucky Cabinet for Human Resources (KDHS), and local public health officials investigated two unrelated outbreaks of acute histoplasmosis in eastern Kentucky. This report summarizes preliminary findings of the investigations of these outbreaks.
Differences in Brain Glucose Metabolism Between Responders to CBT and Venlafaxine in a 16-Week Randomized Controlled Trial
Authors: Sidney H. Kennedy, Jakub Z. Konarski, Zindel V. Segal, Mark A. Lau, Peter J. Bieling, Roger S. McIntyre, Helen S. Mayberg
Journal: American Journal of Psychiatry (2007)

Objective: Neuroimaging investigations reveal changes in glucose metabolism (fluorine-18-fluorodeoxyglucose positron emission tomography [PET]) associated with response to disparate antidepressant treatment modalities, including cognitive behavior therapy (CBT), antidepressant pharmacotherapies, and deep brain stimulation. Using a nonrandomized design, the authors previously compared changes following CBT or paroxetine in depressed patients. In this study, the authors report changes in fluorine-18-fluorodeoxyglucose PET in responders to CBT or venlafaxine during a randomized controlled trial. Methods Subjects meeting DSM-IV-TR criteria for a major depressive episode and a diagnosis of a major depressive disorder received a fluorine-18-fluorodeoxyglucose PET scan before randomization and after 16 weeks of antidepressant treatment with either CBT (N=12) or venlafaxine (N=12). Modality-specific and modality-independent regional brain metabolic changes associated with response status were analyzed. Results: Response rates were comparable between the CBT (7/12) and venlafaxine (9/12) groups. Response to either treatment modality was associated with decreased glucose metabolism bilaterally in the orbitofrontal cortex and left medial prefrontal cortex, along with increased metabolism in the right occipital-temporal cortex. Changes in metabolism in the anterior and posterior parts of the subgenual cingulate cortex and the caudate differentiated CBT and venlafaxine responders. Conclusions: Responders to either treatment modality demonstrated reduced metabolism in several prefrontal regions. Consistent with earlier reports, response to CBT was associated with a reciprocal modulation of cortical-limbic connectivity, while venlafaxine engaged additional cortical and striatal regions previously unreported in neuroimaging investigations.
Adverse effects of spinal manipulation
Authors: Barry J Lewis
Journal: Journal of the Royal Society of Medicine (2007)

Please e-mail letters for publication to Dr Kamran Abbasi [ kamran.abbasi@rsm.ac.uk ]. Letters should be no longer than 300 words and preference will be given to letters responding to articles published in the JRSM. Our aim is to publish letters quickly. Not all correspondence will be acknowledged.
Esrever Hsilgne
Authors: LHEK YELKRAM
Journal: Annals of Internal Medicine (1981)

Ad Libitum1 March 1981Esrever HsilgneLHEK YELKRAM, KEHL MARKLEY, M.D.LHEK YELKRAM, KEHL MARKLEY, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-94-3-409 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptEver get the urge to spell words backward?As a child I began with serutan,Now it's an obsession, hard to pots.Some really gnisuma things can happen.I have a rehtorb and a retsis.The latter has a boy named Sinned.One emit I changed his repaid,And its odor wasn't that of a rewolf.For breakfast we drink our klim;For lunch it is toh god on a rollAnd chocolate ekac for tressed.Afterwards it's Smut for a bellyache.We can take a trip to Wen KroyAnd rid the yawbus downtown,Or better yet fly to... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1981Volume 94, Issue 3Page: 409-409KeywordsChocolate Issue Published: 1 March 1981 PDF downloadLoading ...
A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.
Authors: Gary William Middleton, Juan W. Valle, Jonathan Wadsley, David Propper, Fareeda Y. Coxon, Paul J. Ross, Srinivasan Madhusudan, Tom Roques, David Cunningham, Philippa Corrie, William Greenhalf, Victoria Shaw, Trevor F. Cox, Paul Silcocks, Gemma Nanson, John P. Neoptolemos
Journal: Journal of Clinical Oncology (2013)

LBA4004 Background: GV1001, a promiscuous class II epitope encompassing aa 611-626 of hTERT led to the development of CD4+ clones recognizing hTERT in patients with advanced pancreatic cancer (APC). Preclinically gemcitabine increases antigen cross-presentation, enhances T cell trafficking/activation, and reduces MDSCs and Tregs. Methods: Patients with APC were randomized 1:1:1 to: Arm 1 GemCap; 2 GemCap for 8/52 followed by GV1001 followed by further GemCap if no PD at week 8; 3 concurrent administration of GemCap and GV1001. 735 (69.2%) had metastatic disease and 948 (89.3%) had ECOG PS=0 or 1. Randomization was stratified by stage and PS. Primary endpoint was overall survival (OS); secondary endpoints included ORR, TTP, and AEs. Recruitment target was 1,110 patients (780 deaths) to permit detection of a hazard ratio of 0.748 between either GV1001 arm and Arm 1 using a 2-sided α=0.025 level of significance with at least 80% power. Results: 1,062 pts from 51 centers were randomized. Trial maturity was high (72.7% patients died): median follow-up was 6.11 months. The overall response rates were Arm 1=17.6%; Arm 2=8.9% (p=0.001); Arm 3: 15.5% (p=0.460 compared with Arm 1). Conclusions: OS with concurrent GemCap/GV1001 was not different to that with GemCap alone. OS with sequential GV1001 was not statistically different to GemCap alone as it did not meet the criterion for statistical significance (p&lt;0.0175). The addition of a T helper epitope vaccine to GemCap did not improve outcome compared to GemCap alone. Clinical trial information: 43482138. [Table: see text]